ReviewNeurosurgery practice2026
Peripheral Nerve Surgery and Chemotherapy: A Review, Index, and Decision Tree for Nerve Surgeons Considering Neurotization After Oncological Nerve Injuries.
Review in Neurosurgery practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesChemotherapy-induced peripheral neuropathy (CIPN) is a complication caused by some drugs used to treat cancers including metastatic spine and malignant nerve tumors. Debilitating denervation may result from such tumors directly or from their surgical resection. The inhibitory effects of adjuvant chemotherapy on nerve regeneration in peripheral neurotization surgeries are poorly understood and must be inferred from known mechanisms of CIPN. This narrative review aims to create an index of chemotherapeutics that may cause chemotherapy-associated neurotization failure (CANF) to better inform preoperative counseling, operative timing, and postoperative prognostication by peripheral nerve surgeons.
methodsA narrative review of published English-language literature on CIPN was performed, focusing on its known pathogenic mechanisms and its clinical manifestations including onset, duration of dysfunction, and effect size. The literature was also searched for existing evidence on the effects of the same agents on nerve regeneration and outcomes after peripheral nerve surgery.
resultsCIPN can manifest with sensory, motor, and/or autonomic dysfunction. Platinum-based compounds, taxanes, vinca alkaloids, antimetabolites, and proteasome inhibitors are implicated drug classes, all of which have distinct neurotoxicity profiles. CIPN phenotypes vary in timing, severity, and nerve modalities affected. Some agents are associated with a "coasting" phenomenon, where neuropathy persists even after the offending drug's discontinuation. The neurotoxic milieu induced by chemotherapy likely impairs nerve regeneration, but this has not been addressed in the literature. Data on neurotoxic chemotherapy agents were synthesized and used to create an index and risk-stratified decision tree based on inferred likelihood of CANF.
conclusionDenervated patients on neurotoxic adjuvant chemotherapy regimens pose unique challenges to peripheral nerve surgeons. At least a cursory understanding of CIPN-implicated drugs, mechanisms of neurotoxicity, presentations, and the inferred risk of CANF is recommended before pursuing neurotization surgery. This index serves as a resource for peripheral nerve surgeons in this clinical conundrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.